Basics Iovance Biotherapeutics, Inc. Iovance Biotherapeutics Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases. IPO Date: October 23, 2013 Sector: Healthcare Industry: Biotech Market Cap: $901.02M Activated in VL: True Average Daily Range Avg Daily Range: $0.47 | 3.17% Avg Daily Range (30 D): $0.13 | 4.97% Avg Daily Range (90 D): $0.11 | 4.59% Institutional Daily Volume Avg Daily Volume: 3.47M Avg Daily Volume (30 D): 14.71M Avg Daily Volume (90 D): 15.46M Trade Size Avg Trade Size (Sh.): 163 Avg Trade Size (Sh.) (30 D): 407 Avg Trade Size (Sh.) (90 D): 430 Institutional Trades Total Inst.Trades: 5,249 Avg Inst. Trade: $2.56M Avg Inst. Trade (30 D): $1.29M Avg Inst. Trade (90 D): $1.47M Avg Inst. Trade Volume: .22M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $4.01M Avg Closing Trade (30 D): $1.37M Avg Closing Trade (90 D): $1.59M Avg Closing Volume: 363.67K     News Aug 26, 2025 @ 5:00 PM Untreated Metastatic or Unresectable Melanoma Clin... Source: Delveinsight Aug 24, 2025 @ 1:30 PM 1 Beaten-Down Stock That Could Soar By 261%, Accor... Source: Prosper Junior Bakiny Aug 19, 2025 @ 7:16 PM Why Iovance Biotherapeutics Stock Was Climbing Tod... Source: Eric Volkman Aug 9, 2025 @ 8:21 AM 3 Stocks That Could Turn $1,000 Into $5,000 by 203... Source: James Brumley Jul 29, 2025 @ 7:29 AM This Beaten-Down Healthcare Stock Could Jump 720%,... Source: Cory Renauer Financials   TTM Q1 2025 Q3 2024 Basic EPS $-.33 $-.36 $-.28 Diluted EPS $-.33 $-.36 $-.28 Revenue $ 59.95M $ 49.32M $ 58.56M Gross Profit $ 3.29M $ -.42M $ 18.73M Net Income / Loss $ -111.66M $ -116.16M $ -83.54M Operating Income / Loss $ -113.77M $ -121.22M $ -89.07M Cost of Revenue $ 56.66M $ 49.74M $ 39.82M Net Cash Flow $ -39.64M $ 56M $ -64.57M PE Ratio     Splits Sep 26, 2013:   1:100 Apr 06, 2010:   24:1